Medicine is in full swing! The first global biomedical frontier technology, policy and regulation conference was held

In the past decade, Chinese pharmaceutical companies and biotech companies have grown from few to everywhere Ten years is a life cycle from the start of research and development to the successful listing of new drugs, and also a witness to the rise of China's pharmaceutical industry In recent years, more and more candidate drugs found in China have entered the global clinical trials, including some of the first competitive new drugs But "global new" comes from China and benefits global patients We are still on our way! From a big pharmaceutical country to a powerful pharmaceutical country, from imitation based to comprehensive innovation, China's new drug development has a long way to go Where is the next ten years of innovation worth pondering and discussing! On October 30, 2019, the first global biomedical frontier technology, policy and regulation conference, an epic masterpiece of the 15th anniversary of freehand brushwork, was grandly opened at the Bank of Jinji Lake in Suzhou This conference is sponsored by China food and drug enterprise quality and Safety Promotion Association and Tonghua Yiyi new drug talent club, and co organized by China Pharmaceutical Enterprise Management Association pharmaceutical research and development innovation Committee, BioBAY, biosetto, deepness Zhiyao, Taimei medical technology, East Fulong and many other institutions The conference brought together 200 pharmaceutical heavyweights and more than 1000 industry colleagues from a global perspective to discuss the global frontier technology of biomedicine and the hot direction of policies and regulations with far sighted thought exchange and collision, so as to dedicate the next decade of China's biomedicine At the conference site, more than ten theme reports and round table discussions were called "works" Each scene was elaborately created and designed, attracting countless attention, which led 2000 participants to give up their tea break time and stay in the field to exchange and linger Deputy secretary general and press spokesman of China food and drug enterprise quality and Safety Promotion Association The conference was jointly sponsored by China food and drug enterprise quality and Safety Promotion Association and Tonghua Yixin new drug talent club Using the academic exchange platform, the conference further explored the opportunities, challenges and future development direction of biopharmaceutical research and related industries, further understood the international policies and regulations on biopharmaceutical research and drug management, and accelerated the development of biopharmaceutical innovation and management in China International connection President of China Pharmaceutical Enterprise Management Association It was started 12 years ago and more than ten years later Out of the awe of science, the thirst for knowledge and the passion for innovation, it has gradually developed into the highland and holy palace of China's biomedical science and technology talents and new drug leaders, as well as the Huangpu Military Academy of China's biomedical innovation talents cultivation Director of Suzhou Industrial Park Management Committee Biomedicine is one of the most important growth industries in the world As a professional institution with important influence in the field of new drugs in China, together with freehand brushwork, the top institutions and well-known leaders at home and abroad, held the first global conference on biomedical frontier technology, policies and regulations in the park, and settled the headquarters of Huadong District in the park This conference brought the most cutting-edge technology, the most popular research and development field And industry development trend Director of Jiangsu Drug Administration Welcome to Suzhou to discuss the frontier technology, policies and regulations of biomedical industry, especially at the 15th anniversary of the founding of freehand brushwork Its significance is not only that it is full of friends today, but also that it is just the right time You know that in the past few years, a series of reform effects of drug regulation are gradually emerging This series of reform measures It is promoting the rapid integration of the whole industry Vice chairman of the CPPCC National Committee and executive vice chairman of the Central Committee of the Agricultural Labor Party At the beginning of the report, chairman he expressed his heartfelt thanks for the contribution made by Tongyi new medicine talent club to the development of China's biomedicine in the past 15 years! Academician of the American Academy of Sciences, HCV discoverer, chairman of synergetics LLC Biotechnology development in the United States: innovation and breakthrough My career in vaccine production has brought me a lot of sense of achievement In order to succeed in vaccine development, it is necessary to develop stable surface antigen expression for specific pathogens The higher the antigen stability, the higher the success rate of vaccine development The current pharmaceutical industry is not friendly to vaccine development, and vaccine manufacturing needs more new technologies President of the new medicine talent Club 30 years of agitation (2005-2035): review and prospect and analysis of the future development path of Chinese Pharmaceutical Enterprises Looking back on the past 30 years, the pharmaceutical industry has been in the form of focusing on sales rather than research and production for a long time Fortunately, with the promotion of large-scale pharmaceutical reform, we have begun to have a real sense of pharmaceutical transformation in recent years China's pharmaceutical R & D has gone from version 1.0: pure imitation, version 2.0: me too, me better to version 3.0: independent innovation, synchronous development with overseas countries has a long way to go Let's work hard for the future development of pharmaceutical and health undertakings! Director, Institute of molecular medicine, Peking University, associate editor, New England Journal of medicine Co founder, chairman and CEO of heqirui Pharmaceutical Co., Ltd How far are we from Chinese laboratories to global clinical patients? Our goal is very clear We want to be the first in class We hope to be the international standard innovative medicine that can go global and serve the patients and patients around the world to solve their sufferings China used to go out to sea by boat Now we build our own boats and go out to sea We really hope that the global innovative medicine will come from China and benefit the patients On the way, it is the common dream of our generation to change from a pharmaceutical power to a pharmaceutical power Chairman of Xinda biology Frontier technology and development trend of biological medicine In recent years, with the changes in drug supervision, basic research and national payment system, the essential elements for the development of innovative drugs have undergone revolutionary changes, which is the best era for us to make biological drugs Monoclonal antibodies will continue to lead the development of biopharmaceutical industry in the next 10 years As new products and technologies emerge in endlessly, more and more new biopharmaceutical technologies will be worth breakthrough and expectation in the future Chief scientist of drug evaluation center of State Food and Drug Administration Policy guidance for accelerating the review and approval of innovative drugs President of Beijing jiakesi new drug R & D Co., Ltd SHP2 and KRAS channel, the next wave of heavy bombs after PD-1 Dr Cheng Zengjiang was the first teacher of China's drug approval system when I just returned home At the beginning of the establishment of tongshuyi, we had no idea that our country would have such a big growth in new drug reform Today's dazzling stars have a bleak period of time! Targets that were thought to be difficult or impossible to be made into medicines in the past, such as KRAS, are slowly becoming medicines now The gold of immunology target PD-1 has been cleared out KRAS and SHP2 channels, the next wave of heavy bombs after PD-1, and it is also the current strategy to find some targeted channels with small molecular drugs Chairman of CSCO Special Committee for non-small cell lung cancer, director of Cancer Research Institute, Tongji University Medical College Translational medicine of lung cancer and its latest progress Chinese experts go to the world mainly relying on targeted drugs such as Iressa and Troika These drugs give patients longer survival, but they are all faced with drug resistance, which is the focus of transformation research Clinical research needs to be closely combined with transformation research, and the mechanism of drug resistance is becoming more and more complex Immunotherapy single drug needs to be selected, PD-L1 may be a reliable marker, TMB is in doubt, immunotherapy combined with other therapies is a feasible scheme CEO and chief scientist of Rongchang biopharmaceutical Independent innovation and breakthrough of original biological medicine From three aspects of the innovative thinking of Biopharmaceutics, from clinical innovation: end-line patients, disease subsets, new identified diseases, neglected diseases; from target innovation: new target, old target, difficult target; from production technology innovation: engineering antibody, dual-function antibody, ADC But in general, no matter the old target or the better blocking mechanism, as long as the development of better drugs, it is promising Founder / general manager of microenvironment biotechnology / Suzhou occasionally lead biology Good science makes new drug R & D stronger than weak There are so many difficulties for start-ups, how to win with the weak? Entering the new field of "experience becomes an obstacle to innovation", finding answers from public research, unconventional thinking based on scientific judgment, the unknown is an opportunity, standing on the shoulders of giants (such as me too of dashatini), and deep understanding of regulatory policies are all feasible solutions Freehand FDA commentator Desire driven industries and the pharmaceutical legal environment in the United States The pharmaceutical industry in the United States has a business cycle, which is generally a desire driven industry At present, such a pharmaceutical system in the United States is not replicable, because the United States is too rich to invest in order to survive Scientists want research results, enterprises want economic returns, governments want votes, patients want votes, so some experts say that by 2050, if 50% of GDP can solve other problems, then how can we use the other half of GDP to improve people's health level! Discussion site Host: Huayie: Founder / CEO of Yihui Pharmaceutical Technology Distinguished guest: He Ruyi: chief scientist of SDIC innovation, director of the academic committee of the research center of pharmaceutical regulatory science, Tsinghua University School of Medicine Su Yong: Executive Director / deputy general manager of Zhangjiang, Fudan Sun Yongkui: Chairman of force life science, academician of American Academy of Engineering Lu Xianping: CEO of microchip biology Li Ning: Executive Director / general manager of Junshi biology Chen Li: Chairman of Hualing pharmaceutical Zhao Dayao: CEO of Youhe pharmaceutical The current innovation mode can not be applied under the new 4 + 7 policy, so we need to find new profit points Differentiation should also be based on trends and their own ability to find their own base Innovation systems based on scientific systems and payment systems are believed to be quite different The mission of China's innovation is to let the Chinese people have medicine to eat First, there is medicine to eat, that is, the consistency evaluation of generic drugs Second, we need to establish a new system of drug innovation and find new ways to solve the long-term needs of human diseases Is the capital market encouraging innovation and supporting innovative industries the key to innovation breakthrough To make a breakthrough in new drugs in China, we must have stable policy support, continuity, scientificity, compliance and internationalization China's pharmaceutical industry was a child ten years ago, and may become an adult leading the pharmaceutical industry in Europe and the United States ten years later I hope we can lead each other to grow up at that time.